This activity is expired and is no longer available for CME credit.


Advancing Therapy for IBD Through Novel Mechanisms and Emerging Agents: A Rapid-Fire Roundtable Discussion

Author(s)/Faculty: Britt Christensen, BSc, MBBS (Hons), MPH; Millie D. Long, MD, MPH; Alan C. Moss, MD, AGAF; David T. Rubin, MD, AGAF
Release Date: 3/31/2020Expiration Date: 3/30/2021
Credit Type: AANP / AAPA / CMENumber of Credits: 0
Content Type: LectureProvider:
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic, frequently progressive condition that affects approximately 3 million people in the United States. Inflammatory bowel disease is associated with significant morbidity, diminished quality of life, and, in some cases, mortality. To meet the persistent challenges associated with managing patients with moderate to severe IBD, health care professionals must be knowledgeable regarding the wide variety of existing and emerging agents to treat these diseases. Ongoing education is required to remain current regarding the evidence-based and expert-recommended strategies for managing IBD. In this CME activity, expert faculty describe the pathogenesis of IBD and the mechanisms of action of existing and novel therapies as well as assess the clinical evidence to support the safety and efficacy of emerging agents for treating patients with IBD. This activity will feature Rapid-Fire Roundtable, an engaging, fast-paced exchange of clinical expert perspectives to promote enhanced learning.